Quest Laboratories PE ratio history and valuation
NSE: QUESTLABPharmaceuticals & Biotechnology
Share price at the NSE close on 27 Oct 2026. Previous close ₹84.00.
27 Oct: open ₹82.00, high ₹84.00, low ₹81.95
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. Market capitalisation: how it is worked out
- ₹134 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 93,60098.7% delivered
Quest Laboratories' dividend yield on 27 Oct 2026, each against its own history of up to 3 years. It has no P/E yet: twelve months of its results are not on record.
Quest Laboratories PE ratio and valuation against its own history
- Price to earningsNo results for a period ending in the last six months, or nine for a company filing half-yearly
- Price to bookNo results for a period ending in the last six months, or nine for a company filing half-yearly
- Price to salesPrice to sales, trailing. Market cap divided by the revenue of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what investors pay for each rupee of a year's sales.No results for a period ending in the last six months, or nine for a company filing half-yearly
- EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.No results for a period ending in the last six months, or nine for a company filing half-yearly
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.0.00%today
1 year
Median 0.00%Today is at or above 100% of the 243 days
3 years, since Jun 2024
Median 0.00%Today is at or above 100% of the 583 days
- Earnings yieldEarnings yield. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) as a percentage of market cap, the P/E turned upside down.No results for a period ending in the last six months, or nine for a company filing half-yearly
Each track ranks every trading day in the window from the day the ratio was lowest to the day it was highest; the dot is today. The share under it is how many of those days the ratio was at or below today's level, so a high share means today is higher than on most days in the window. A window is shown only when the ratio is held on most of its trading days; a day after a loss-making year has no P/E. Dividend yield is in per cent. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
How each ratio is worked out, with today's figures
- Market cap =Close×Shares in issueShares in issue. The shares in issue in the latest shareholding filing.1,63,87,200at 30 Sep 2026
₹ crore.Quest Laboratories financials ›
Quest Laboratories valuation at each year end
On the last trading day of each March, the month the company's year ends.
| Ratio | Mar 2025 | Mar 2026 |
|---|---|---|
| Market cap (₹ crore) | 168 | 171 |
| Price to earnings | 14.2 | No full year |
| Price to book | No balance sheet | 1.9 |
| Price to sales | 2.0 | No full year |
| EV to EBITDA | No balance sheet | No full year |
| Dividend yield | 0.00% | 0.00% |
| Earnings yield | 7.0% | No full year |
Quest Laboratories market cap, since Jun 2024
The last trading day of each month.
Market cap, ₹ crore
- Market cap
Dividends and the public's market cap
From the close on 27 Oct 2026.
- Dividends, last 12 monthsDividends per share, last 12 months. Dividends per share with an ex-date in the last twelve months, restated for any split or bonus since.
- None
- Public's market capPublic's market cap. The market value of the shares held by everyone other than the promoters, the group that set up or controls the company.
- ₹45 Cr
Against Pharmaceuticals
216 listed companies in Pharmaceuticals, each priced on its last trading day; Quest Laboratories is 144th among them by market cap. Each median leaves out Quest Laboratories itself and takes the other companies that have the figure.
- Industry median P/EIndustry median trailing P/E. The middle trailing P/E of the listed companies in the same industry that have one, leaving out the company itself and any P/E above 200.
- 28.4Across 159 other companies
- Industry median P/BIndustry median P/B. The middle P/B of the listed companies in the same industry that have one, leaving out the company itself.
- 3.0Across 191 other companies
- Industry median EV/EBITDAIndustry median EV/EBITDA. The middle EV/EBITDA of the listed companies in the same industry that have one, leaving out the company itself.
- 19.9Across 147 other companies
- Industry median dividend yieldIndustry median dividend yield. The middle dividend yield of the listed companies in the same industry that paid a dividend in the last twelve months, leaving out the company itself.
- 0.50%Across 89 other companies
| Company | |||||
|---|---|---|---|---|---|
 Curis LifesciencesCURIS | 146 | 21.04 | 3.07 | 14.7 | 0.00% |
 Auro LaboratoriesAUROLAB | 142 | 30.21 | 3.05 | 15.6 | 0.00% |
 Panchsheel OrganicPANCHSHEEL | 135 | 13.14 | 0.96 | 10.5 | 3.12% |
 Par Drugs and ChemicalsPAR | 135 | 9.30 | 1.20 | 4.7 | 0.00% |
| Quest LaboratoriesQUESTLAB | 134 | – | – | – | 0.00% |
 Bal PharmaBALPHARMA | 132 | 18.35 | 1.61 | 8.5 | 1.45% |
 Krebs Biochemicals and IndustriesKREBSBIO | 129 | – | – | – | 0.00% |
 Lactose (India)LACTOSE | 128 | 18.46 | 1.97 | 9.7 | 0.00% |
 Speciality MedicinesSPML | 124 | 9.51 | 1.74 | – | 0.00% |
Stakes in other listed companies
At market prices on 27 Oct 2026. Not published: the stakes are worth 2.3% of the company's own market cap, under the 25% this figure is about.
- Its own market capIts own market cap. Closing price × shares in issue.
- ₹134 Cr
- Its stakes, at marketIts stakes, at market. Each stake's per cent × that company's market cap, added up.
- ₹3.12 Cr
- Choksi Laboratories2.04%₹3.12 Cr